AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34507574
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl 12 mcg/h
Trial: 34507574
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine 10 mg b.i.d.
Trial: 34509409
Drug: Patient-worn accelerometers
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-worn accelerometers measuring Physical Average Daily Activity (PADA)
Trial: 34509409
Drug: Patient-worn accelerometers
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-worn accelerometers measuring Total Average Daily Activity
Trial: 34510123
Drug: Potential genetic
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential genetic targets for SSNHL treatments
Trial: 34510485
Drug: Frequent antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent antibiotic courses
Trial: 34511132
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy (n = 67)
Trial: 34511975
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of plasma PTX3 levels and PR
Trial: 34513679
Drug: CD-19 CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD-19 CAR-T immunotherapy (second generation CAR containing CD28 or 4-1BB therapy)
Trial: 34513681
Drug: Biodegradable rectal
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biodegradable rectal spacer balloon
Trial: 34514436
Drug: SARS-CoV-2 mRNA
RxNorm normalized name: SARS-CoV-2 mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 mRNA vaccines (Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273)
Trial: 34515215
Drug: HKT288 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HKT288 (0.3 mg/kg IV every 3 weeks)
Trial: 34515215
Drug: HKT288 (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HKT288 (0.75 mg/kg cohort)
Trial: 34515215
Drug: HKT288 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HKT288 (0.3 mg/kg IV)
Trial: 34516954
Drug: Tisagenlecleucel (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisagenlecleucel (target dose 5 × 10^5 CAR T cells)
Trial: 34518090
Drug: Hyperuricemic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperuricemic group (SUA > 7 mg/dl in men, > 6 mg/dl in women)
Trial: 34518162
Drug: Anti-VEGF therapy
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF therapy initiation during lockdown (16 March 2020 through 31 July 2020)
Trial: 34518162
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (sham-control arm data from Minimally Classic/Occult Trial)
Trial: 34519109
Drug: High PPI
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High PPI dose (≥ 20 OE/day)
Trial: 34519839
Drug: anti-CD47 antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-CD47 antibodies
Trial: 34519839
Drug: anti-CD47 antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-CD47 antibodies + IFN-α
Trial: 34520127
Drug: Fluzone® Quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzone® Quadrivalent (IIV4) vaccine
Trial: 34520638
Drug: Systemic antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antidepressant treatments
Trial: 34520638
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic antidepressant treatments
Trial: 34521113
Drug: mAb CAEL-101
RxNorm normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mAb CAEL-101 (11-1F4) administered as a single intravenous infusion with escalating doses from 0.5 mg/m2 to 500 mg/m2 in phase 1a and as 4 weekly infusions in phase 1b.
Trial: 34523045
Drug: Management according
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management according to ophthalmic and systemic disease
Trial: 34524220
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon α-2b (HD-IFN)
Trial: 34524647
Drug: Procalcitonin <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin < 0.1 ng/mL
Trial: 34525286
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg vaccine
Trial: 34525286
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg vaccine
Trial: 34525286
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg and 2 mg vaccines
Trial: 34526044
Drug: Sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200 mg d1, every 3 weeks, until disease progression, unacceptable toxicity, or up to 35 cycles) + SBRT (8 Gy × 3) + GM-CSF (125 μg/m)
Trial: 34526151
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavior Therapy (G-CBT) for 3 months
Trial: 34526151
Drug: Individual Outpatient
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Outpatient Treatment (IOT) for 3 months
Trial: 34526151
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavior Therapy (G-CBT)
Trial: 34526151
Drug: Individual Outpatient
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Outpatient Treatment (IOT)
Trial: 34526343
Drug: Monthly self-report
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly self-report of falls (including number and severity) confirmed through interviews
Trial: 34526804
Drug: iota-carrageenan containing
RxNorm normalized name: iota-Carrageenan
DrugBank: iota-Carrageenan (DB15304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iota-carrageenan containing lozenge
Trial: 34527608
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (sorafenib followed by yttrium 90 glass microspheres)
Trial: 34528591
Drug: MPFF +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF + compression + topical treatment
Trial: 34528591
Drug: MPFF +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF + compression + topical treatment + endovasal laser coagulation
Trial: 34528591
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving topical treatment
Trial: 34528591
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not receiving compression therapy
Trial: 34528591
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving compression therapy
Trial: 34528763
Drug: Poziotinib 12
RxNorm normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poziotinib 12 mg orally once daily for 28-day cycle
Trial: 34529182
Drug: Inhaled prostacyclin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled prostacyclin analogues
Trial: 34529182
Drug: Inhaled epoprostenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled epoprostenol (VPCOVID [NCT04452669])
Trial: 34529226
Drug: No antirheumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antirheumatic drug intake
Trial: 34529255
Drug: Antibiotics initiated
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antibiotics initiated for presumed bacterial respiratory tract co-/superinfection
Trial: 34529255
Drug: Drivers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drivers of antibiotic prescribing
Trial: 34529762
Drug: AZD1222 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1222 vaccine (1 dose)
Trial: 34529930
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) with dosing of 54 Gy in three fractions for peripheral lesions or 50 Gy in four fractions for central tumours (totaling 60 Gy).
Trial: 34529930
Drug: Video-assisted thoracoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND)
Trial: 34529983
Drug: Cockcroft-Gault creatinine
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cockcroft-Gault creatinine clearance (C-G)
Trial: 34530728
Drug: Psychotropic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic drug prescriptions (PTDs)
Trial: 34530728
Drug: Antipsychotic prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic prescriptions
Trial: 34530728
Drug: Sedatives/hypnotics prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedatives/hypnotics prescriptions
Trial: 34530733
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment initiation
Trial: 34530744
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for COVID-19 patients
Trial: 34530760
Drug: Pyrotinib 400
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 400 mg once daily and thalidomide 200 mg once daily until disease progression or intolerable toxicity
Trial: 34530760
Drug: Pyrotinib 400
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 400 mg once daily and thalidomide 200 mg once daily
Trial: 34530793
Drug: Internal fixation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal fixation treatment for lower limb fractures
Trial: 34531249
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg on day 1 and carboplatin AUC 2 on days 8 and 15 of a 3-week cycle until progression
Trial: 34531250
Drug: CD33-directed chimeric
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD33-directed chimeric antigen receptor T cell immunotherapy (CD33CARTs) with CD28 costimulatory domain
Trial: 34531250
Drug: CD33-directed chimeric
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD33-directed chimeric antigen receptor T cell immunotherapy (CD33CARTs) with 4-1BB costimulatory domain
Trial: 34531279
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose potassium treatment
Trial: 34531279
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose potassium treatment
Trial: 34531443
Drug: Collar Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collar Therapy Indicator (COTI) for monitoring radioactive iodine uptake
Trial: 34531588
Drug: Chimeric antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor (CAR) T-cells
Trial: 34531755
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) treatment, specific dosage and duration not available
Trial: 34533472
Drug: SARS-CoV-2 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 antibodies measured in saliva
Trial: 34533772
Drug: No inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No inhalation technique errors
Trial: 34533772
Drug: Inhalation technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation technique errors
Trial: 34533772
Drug: Adhering to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhering to medication
Trial: 34533772
Drug: Not adhering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not adhering to medication
Trial: 34533772
Drug: PIF measurements,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIF measurements, inhalation technique, medication adherence
Trial: 34534421
Drug: Long-Acting Injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-Acting Injectable Antipsychotic Medication plus Customized Adherence Enhancement
Trial: 34534430
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (6.4 mg per kilogram of body weight)
Trial: 34535360
Drug: Initial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial insulin therapy for ≥3 months
Trial: 34536405
Drug: Onasemnogene abeparvovec
RxNorm normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Onasemnogene abeparvovec gene therapy (1·1×10^14 vg/kg) administered as a one-time intravenous infusion.
Trial: 34539356
Drug: CT38s at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT38s at an infusion rate of 0.03 μg/kg/h
Trial: 34540013
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy plus apatinib (250 mg/day for 28 days)
Trial: 34540651
Drug: Molecular profiling
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular profiling for tailoring adjuvant therapy in the high-intermediate-risk group
Trial: 34540697
Drug: Low-dose apatinib
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose apatinib combined with S-1
Trial: 34540703
Drug: Low-dose craniospinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose craniospinal irradiation (18 Gy)
Trial: 34540919
Drug: Aspirin for
RxNorm normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin for primary prevention of cardiovascular disease
Trial: 34541429
Drug: Surgery or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery or medical treatments for diverticular disease
Trial: 34541429
Drug: Medical treatments,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatments, interventional radiology, and surgery
Trial: 34542729
Drug: Arterial stiffness
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arterial stiffness measures (pulse wave velocity, augmentation index) and HRV indices
Trial: 34543383
Drug: Uproleselan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uproleselan (10 mg/kg twice daily) plus MEC (mitoxantrone, etoposide, and cytarabine)
Trial: 34543383
Drug: Uproleselan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uproleselan (10 mg/kg twice daily) plus cytarabine and idarubicin (7 + 3)
Trial: 34543383
Drug: Uproleselan added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uproleselan added to chemotherapy
Trial: 34543477
Drug: Chemotherapy (platinum-based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (platinum-based, four to six cycles)
Trial: 34544269
Drug: Dual compartment
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual compartment suppositories
Trial: 34544430
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal challenge (50 g fat)
Trial: 34548050
Drug: Concurrent wasting-stunting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent wasting-stunting
Trial: 34548321
Drug: LY3200882 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3200882 monotherapy
Trial: 34548321
Drug: LY3200882 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3200882 in combination therapy
Trial: 34548324
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition administered in the first 7 days of postnatal life
Trial: 34550085
Drug: Microbial Ecosystem
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbial Ecosystem Therapeutic (MET)-2, daily orally administered capsule containing 40 bacterial strains for 6 weeks
Trial: 34550633
Drug: TOP2 poison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOP2 poison chemotherapy
Trial: 34551725
Drug: Veterans Administration
RxNorm normalized name: benzalkonium chloride Topical Foam [Veteran Shield 24]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veterans Administration Video Connect (VVC)
Trial: 34551886
Drug: Venetoclax (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (400 mg daily for days 1 to 28), Pomalidomide (daily for days 1 to 21), Dexamethasone (weekly for each 28-day cycle)
Trial: 34551886
Drug: Venetoclax (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (400 mg daily for days 1 to 28)
Trial: 34551940
Drug: Maternal vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal vitamin B exposure (exact dosage and duration not specified)
Trial: 34552007
Drug: Epigenetic inhibitors,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epigenetic inhibitors, specific agents not mentioned, duration not specified.
Trial: 34552007
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors, specific agents not mentioned, duration not specified.
Trial: 34552864
Drug: ACY-241 (citarinostat)
RxNorm normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACY-241 (citarinostat) at 180 mg
Trial: 34552864
Drug: ACY-241 (citarinostat)
RxNorm normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACY-241 (citarinostat) at 360 mg
Trial: 34552864
Drug: ACY-241 (citarinostat)
RxNorm normalized name: Citarinostat
DrugBank: Citarinostat (DB15449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACY-241 (citarinostat) at 480 mg
Trial: 34552864
Drug: Nivolumab at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab at 240 mg
Trial: 34552937
Drug: Ayurvedic Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic Nutritional Therapy
Trial: 34552937
Drug: Conventional Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Nutritional Therapy including Low-FODMAP Diet
Trial: 34553156
Drug: Elagolix 200
RxNorm normalized name: elagolix 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix 200 mg administered in early follicular phase
Trial: 34553156
Drug: Elagolix 200
RxNorm normalized name: elagolix 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix 200 mg administered in midluteal phase
Trial: 34553156
Drug: Elagolix 200
RxNorm normalized name: elagolix 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix 200 mg administered in late follicular phase
Trial: 34555420
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally and misoprostol 800 mcg buccally dispensed by mail-order pharmacy after in-person clinical assessment
Trial: 34555420
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally and misoprostol 800 mcg buccally dispensed by mail-order pharmacy
Trial: 34556099
Drug: Proposed solutions
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed solutions for ethical involvement of adolescents in HIV research